Journal
JACC-CARDIOVASCULAR INTERVENTIONS
Volume 8, Issue 13, Pages 1657-1666Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2015.08.013
Keywords
coronary artery disease complexity; drug-eluting stent(s); percutaneous coronary intervention; SYNTAX score
Categories
Funding
- Italian Society of Cardiology
- Veronesi Foundation
- Medtronic
- Biotronik
- Veronesi Foundation-Cardiovascular research
- AstraZeneca
- Biosensors International
- Eli Lilly
- Medicines Company
- Abbott Vascular
- Biosensors
- St. Jude Medical
- Abbott
- Boston Scientific
- Edwards Lifesciences, Inc.
- St. Jude
Ask authors/readers for more resources
OBJECTIVES The purpose of this study was to compare the 2-year safety and effectiveness of new-versus early-generation drug-eluting stents (DES) according to the severity of coronary artery disease (CAD) as assessed by the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score. BACKGROUND New-generation DES are considered the standard-of-care in patients with CAD undergoing percutaneous coronary intervention. However, there are few data investigating the effects of new-over early-generation DES according to the anatomic complexity of CAD. METHODS Patient-level data from 4 contemporary, all-comers trials were pooled. The primary device-oriented clinical endpoint was the composite of cardiac death, myocardial infarction, or ischemia-driven target-lesion revascularization (TLR). The principal effectiveness and safety endpoints were TLR and definite stent thrombosis (ST), respectively. Adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated at 2 years for overall comparisons, as well as stratified for patients with lower (SYNTAX score <= 11) and higher complexity (SYNTAX score >11). RESULTS A total of 6,081 patients were included in the study. New-generation DES (n = 4,554) compared with earlygeneration DES (n = 1,527) reduced the primary endpoint (HR: 0.75 [95% CI: 0.63 to 0.89]; p = 0.001) without interaction (p = 0.219) between patients with lower (HR: 0.86 [95% CI: 0.64 to 1.16]; p = 0.322) versus higher CAD complexity (HR: 0.68 [95% CI: 0.54 to 0.85]; p = 0.001). In patients with SYNTAX score >11, new-generation DES significantly reduced TLR (HR: 0.36 [95% CI: 0.26 to 0.51]; p < 0.001) and definite ST (HR: 0.28 [95% CI: 0.15 to 0.55]; p < 0.001) to a greater extent than in the low-complexity group (TLR p(int) = 0.059; ST p(int) = 0.013). New-generation DES decreased the risk of cardiac mortality in patients with SYNTAX score >11 (HR: 0.45 [95% CI: 0.27 to 0.76]; p = 0.003) but not in patients with SYNTAX score <= 11 (p(int) = 0.042). CONCLUSIONS New-generation DES improve clinical outcomes compared with early-generation DES, with a greater safety and effectiveness in patients with SYNTAX score >11. (C) 2015 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available